APOE and Alzheimer disease: Moreover, patients who are apolipoprotein E ε4 (APOE4) gene carriers, especially those who are homozygotes, are at higher risk for AD development, but also for ARIA during treatment with lecanemab [50], and the AUR recommends APOE genotyping to identify patients who are candidates to receive lecanemab [52].